Alumis (NasdaqGS:ALMS) FY Conference Transcript

Summary of Alumis Conference Call Company Overview - Company: Alumis - Event: Oppenheimer's Annual Healthcare Conference - Key Speakers: Martin Babler (CEO), John Schroer (CFO) Core Industry and Product Insights Psoriasis Treatment - Product: Envudeucitinib - Phase 3 Data: Positive top-line results announced in January - Primary Endpoint Results: - PASI 75: Average of 74% - sPGA 0/1: Average of 59% at week 16 [3][4] - Secondary Results: - PASI 90: Approximately 65% at week 24 - PASI 100: Just over 40% on average [5] - Safety Profile: Consistent with Phase II results; common side effects include headaches, upper respiratory infections, and acne. No malignancy signals observed [6][15][19]. Competitive Landscape - Competitors: J&J's IL-23 blocker and Takeda's TYK2 inhibitors - Market Positioning: Emphasis on the unique benefits of the TYK2 pathway, including improved patient-reported outcomes and quality of life [7][9]. - Dosing Preference: Market research indicates a preference for a twice-daily dosing regimen without food effects over a once-daily regimen with fasting requirements [11][12]. Regulatory and Commercial Plans - NDA Submission: Planned for the second half of the year, contingent on 48-week data [25]. - Commercial Strategy: Strong plan in place, with considerations for potential partnerships due to the broad indication landscape [26]. Future Opportunities Systemic Lupus Erythematosus (SLE) - Unmet Need: High demand for effective oral treatments; current approved drugs have low efficacy [27]. - Ongoing Trial: Phase 2b trial with over 400 patients, primary endpoint BICLA, results expected in Q3 [28]. - Execution Strategy: Focus on patient selection and managing co-medications to minimize placebo rates [30]. Pipeline Developments - Lonigutamab: Ongoing evaluation of its mechanism and competitive landscape; potential for CNS indications [39][41]. - CNS Penetrant TYK2: Consideration of broader applications beyond CNS [39]. Additional Considerations - Malignancy Concerns: No significant malignancy signals observed; background rates of cancer in trials acknowledged [18][21]. - FDA Guidance: Recent communications suggest potential for single trial approvals, which could impact SLE trial strategy [35][36]. This summary encapsulates the key points discussed during the conference call, highlighting Alumis's strategic positioning, product developments, and future opportunities in the healthcare market.